BOSTON--(BUSINESS WIRE)--Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software based on ground truth histology to support treatment of cardiovascular ...
BOSTON--(BUSINESS WIRE)--Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, has added ...
BOSTON, December 03, 2025--(BUSINESS WIRE)--Elucid has announced new Hospital Outpatient Prospective Payment (OPPS) and Physician Fee Schedule (PFS) decisions from the U.S. Centers for Medicare & ...
Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ(TM) ...
Opportunity to demo the only FDA-cleared, non-invasive plaque analysis based on objective ground truth histology, the gold standard for characterization of plaques Elucid CEO Kelly Huang, PhD, will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results